According to recent reports, immunotherapy failure may be related to upregulation of various immune checkpoints in glioma patients after blocking the PD1/PDL-1 pathway (24), indicating the importance of deciphering novel biomarkers for an additive or synergistic impact on glioblastoma patients to guide and improve immune-mediated therapy concepts (25, 26). This evidence concerns the gene PDCD1 and central nervous system cancer.